Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 10Brain Neoplasms 8Myelodysplastic Syndromes 7Neoplasm Metastasis 6Leukemia, Lymphocytic, Chronic, B-Cell 6Glioblastoma 6Recurrence 5Lymphoma 5Glioma 5Sarcoma 4Leukemia 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Astrocytoma 4Ovarian Neoplasms 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms, Neuroepithelial 2Nasopharyngeal Carcinoma 2Mouth Neoplasms 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Interleukin-2 9Melphalan 8CTLA-4 Antigen 8sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7tebentafusp 6Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Bevacizumab 5aldesleukin 4aflibercept 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Blood Specimen Collection 4Biopsy 4trametinib 3sotrastaurin 3relatlimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Uveal Melanoma × Valproic Acid × Clear all
NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Thomas Jefferson University

Phase 2 Active not recruiting
210 enrolled
Dermatologic

Uveal Melanoma

NCT04729543 2023-12-04

MC2TCR

Erasmus Medical Center

Phase 1/2 Recruiting
20 enrolled
DermatologicHead & Neck

Uveal Melanoma, Head and Neck Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡